Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
IPO Year:
Exchange: NASDAQ
Website: vaxart.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2024 | $4.00 | Outperform | Oppenheimer |
| 12/29/2021 | $13.00 → $12.00 | Buy | Jefferies |
| 11/2/2021 | $15.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/29/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/24/2021 | $13.00 | Buy | Jefferies |
4 - Vaxart, Inc. (0000072444) (Issuer)
SC 13G/A - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 shares and restricted stock unit awards covering 97,500 shares, and (ii) Laurie Hastings, our recently-appointed Senior Vice President, Human Resources, consisting of a stock option to purchase 300,000 shares and a restricted stock unit award covering 67,000 shares, in each case as a material inducement
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 20, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13751819 Investors may submit written questions in advance of the conference call
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. "We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improved immune responses of our second-generation constructs," said Steven Lo, Chief Executive Officer of Vaxart. "As norovirus continues to spread across the United States and globally, it has never be
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that complete data from the Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults (55-80 years) (NCT04854746) have been published in Science Translational Medicine. The data, which show strong and durable antibody responses and induction of norovirus-specific antibody and T cell responses, support immunogenicity of the vaccine candidate in a patient population that often has age-related reductions in immune responses to injected vaccines.1,2 Norovirus is a highly contagious virus that causes acute gastroenteritis (AGE) and can lead to substanti
Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve
COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Norovirus program to proceed with Phase 1 study following scientific advisory board and FDA feedback; Trial to initiate the first half of 2025 with topline data expected as early as mid-2025 New avian influenza vaccine candidate being tested in preclinical studies SOUTH SAN FRANCISCO, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today provided business updates as the Company continues to advance its oral pill vaccine platform. "We continue to execute on our lead COVID-1
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the trial to enrollment of 10,000 participants, upon favorable review from the U.S. Food and Drug Administration (FDA) and upon Biomedical Advanced Research and Development Authority (BARDA) approval SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that an independent DSMB, which conducted a planned review of the 30-day safety data from a sentinel cohort of 400 participants in its COVID-19 Phase 2b trial, has recommended that the study conti
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. "We are pleased to complete the enrollment of the sentinel cohort, an important milestone that reflects the collaboration of our entire team, as well as the trust and commitment of the participants and investigators involved," said Dr. James F. Cummin
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart. The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart's common stock, which vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share exercise price equal to the
Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00
Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00
B. Riley Securities downgraded Vaxart from Buy to Neutral and set a new price target of $9.00 from $13.00 previously
B. Riley Securities downgraded Vaxart from Buy to Neutral and set a new price target of $9.00 from $13.00 previously
Jefferies initiated coverage of Vaxart with a rating of Buy and set a new price target of $13.00
Piper Sandler initiated coverage of Vaxart with a rating of Overweight and set a new price target of $18.00
B. Riley resumed coverage of Vaxart with a rating of Buy and set a new price target of $13.00 from $16.00 previously
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
DEF 14A - Vaxart, Inc. (0000072444) (Filer)
SCHEDULE 13G - Vaxart, Inc. (0000072444) (Subject)
PRE 14A - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
424B5 - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
10-K - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that W. Mark Watson was appointed to the Company's Board of Directors, effective August 4, 2022. Mr. Watson will become Chair of the Company's Audit Committee, effective October 1. Robert A. Yedid, a member of the Board and the Audit Committee, was appointed Interim Chairperson of the Audit Committee, to serve until Mr. Watson becomes Chair. "We are very excited to welcome Mark to the Board, whose skills and experience will help us advance our strategy to develop potentially transformative oral pi
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutical Inc., where he served as VP, Deputy General Counsel since 2018. "Ed has more than 25 years of experience advising biotech and pharma companies, and we are excited to benefit from his acumen as
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ:VXRT), today announced the appointment of James F. Cummings, M.D., as the Company's Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development. He joins Vaxart as the Company prepares to begin its Phase II clinical trials for COVID-19 with an oral tablet formulation. "We are excited to have a professional of Dr. Cummings' caliber join Vaxart at this pivotal time to advance our COVID-19 and nor
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a health policy leader and physician with more than three decades of global experience in the pharmaceutical industry coordinating the interests of public companies, trade groups and regulators. "We welcome Dr. Wheadon to our Board of Directors," said Andrei Floroiu, chief executive officer of Vaxart. "His significant experience working in multi-national regulatory envir
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 after the market close on Thursday, March 20, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 20, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13751819 Investors may submit written questions in advance of the conference call
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2024. "Our successful initiation of sentinel cohort dosing is a testament to our rapid execution in helping to ensure that we remain on track to meet the milestones of our Biomedical Advanced Research Development Authority (BARDA) contract," said Steven Lo, Vaxart's Chi
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, November 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13749666 Investors may submit written questions in advance of
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the second quarter of 2024. "We achieved meaningful progress on our clinical, regulatory and operational goals during the first half of 2024," said Steven Lo, Vaxart's Chief Executive Officer. "Most s
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, August 8, 2024 – 4:30 p.m. ETDomestic: (866) 682-6100International: (862) 298-0702Conference ID: 13747081 Investors may submit written questions in advance of the conference call
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024 Anticipates meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the first quart
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Monday, May 13, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13745591 Investors may submit written questions in advance of the conferenc
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 14, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13744368 Investors may submit written questions in advance of the conference call to [email protected]. A repla
Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company's oral pill vaccine platform now established in two human challenge studies for norovirus and influenza Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the third quarter of 2023. "During the third quarter, we took important steps toward validating our mucosal vaccine platform with the release of topline data from